Every 8-K that Allogene Therapeutics, Inc. (ALLO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALLO filings page.
Allogene Therapeutics, Inc. (ALLO) announced that Geoffrey Parker, its Executive Vice President, Chief Financial Officer and principal financial officer, has notified the company of his retirement from all positions. His retirement will be effective November 6, 2026, following notice given on August 31, 2026. The report is signed by President and Chief Executive Officer Zachary Roberts, M.D., Ph.D.
Allogene Therapeutics, Inc. reported second quarter 2026 results and key clinical updates. The pivotal Phase 2 ALPHA3 trial in first-line large B-cell lymphoma showed interim minimal residual disease (MRD) data at the protocol-defined cutoff: 58.3% (7/12) of patients in the cema-cel arm achieved MRD negativity versus 16.7% (2/12) in the observation arm, a 41.6% absolute difference. Following review of this futility analysis, the FDA granted RMAT and Fast Track designations for cema-cel as first-line consolidation therapy in high-risk LBCL.
The company has already activated more than 80 ALPHA3 sites and now expects about 100 sites by year-end 2026, with enrollment of approximately 220 MRD+ patients projected to complete by year-end 2027 and an event-free survival update anticipated in mid-2027. In autoimmune disease, the Phase 1 RESOLUTION trial of ALLO-329 continues brisk enrollment, with a clinical and translational update expected in Q4 2026.
For Q2 2026, Allogene reported $4.64 million in collaboration revenue, $30.7 million in research and development expense and $20.8 million in general and administrative expense. Net loss was $42.7 million, or $0.13 per share, compared with $50.9 million a year earlier. Cash, cash equivalents and investments totaled $423.6 million as of June 30, 2026, and the company projects its cash runway into 2029. 2026 operating expense guidance is approximately $165 million (GAAP operating expenses about $225 million, including roughly $35 million of non-cash stock-based compensation).
Allogene Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders and related corporate actions. Stockholders elected three Class II directors to serve until the 2029 annual meeting and approved, on an advisory basis, the compensation of named executive officers and an annual say-on-pay vote.
Stockholders also approved an amendment to increase authorized common shares from 400,000,000 to 800,000,000, which became effective on June 18, 2026. They ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026. Separately, the company filed a prospectus supplement covering sales of common stock with an aggregate offering price of up to $135.0 million under an existing Sales Agreement with TD Securities (U.S.A.) LLC.
Allogene Therapeutics announced that its Board appointed Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer, succeeding David Chang, M.D., Ph.D. effective July 1, 2026. Dr. Chang’s last day as President and CEO will be June 30, 2026, after which he will remain on the Board as a non-employee director.
On the Effective Date, Dr. Roberts will also join the Board as a Class I director, serving until the 2028 annual meeting or until a successor is elected and qualified. He currently serves as Executive Vice President, Research and Development, and Chief Medical Officer, and will continue as Chief Medical Officer on an interim basis.
His new compensation includes an annualized base salary of $680,000, an annual target cash incentive of 60% of base salary, an option to purchase 476,190 shares, and a restricted stock unit award of 134,530 shares, all subject to service-based vesting. Both Dr. Roberts and Dr. Chang are entitled to severance and change in control benefits under the company’s existing Severance Plan as described in its April 30, 2026 proxy statement.
Allogene Therapeutics reported first quarter 2026 results and a major portfolio change. The company terminated its exclusive license with Overland covering four CAR T targets in parts of Asia, with no termination payments, and restructured its Overland ownership and governance; Allogene now expects to hold about 3% of Overland’s equity.
Interim data from the pivotal Phase 2 ALPHA3 trial showed 58.3% of patients on cemacabtagene ansegedleucel achieved minimal residual disease clearance versus 16.7% on observation, with a 97.7% median ctDNA reduction and no CRS, ICANS, GvHD, treatment-related serious events or hospitalizations. In autoimmune disease, nine patients have been treated in the Phase 1 RESOLUTION trial of ALLO-329 with early signs of activity and favorable tolerability.
Research and development expense was $32.0 million and general and administrative expense was $14.1 million, leading to a net loss of $42.6 million, or $0.18 per share. Allogene ended the quarter with $266.9 million in cash, cash equivalents and investments, and an April 2026 public offering added $200.4 million in gross proceeds, extending projected cash runway into the first quarter of 2029. The company now guides 2026 operating cash expense to about $165 million and GAAP operating expenses to about $225 million.
Allogene Therapeutics, Inc. is raising capital through an underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, for expected gross proceeds of $175 million before fees and expenses. The company granted underwriters a 30-day option to buy up to 13,125,000 additional shares at the same public price, less discounts and commissions. Allogene plans to use the net proceeds for general corporate purposes, including clinical trial, research and development, general and administrative costs, and capital expenditures. The offering is being made under an effective shelf registration on Form S-3 and is expected to close around April 16, 2026, subject to customary conditions.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its allogeneic CAR T pipeline. The pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma is underway, with an interim futility analysis focused on MRD clearance and early safety planned for April 2026.
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026. The company ended Q4 2025 with $258.3 million in cash, cash equivalents and investments, guiding that its cash runway extends into the first quarter of 2028. Full-year 2025 net loss was $190.9 million, or $0.87 per share.
Allogene Therapeutics (ALLO) furnished an 8‑K stating it provided a corporate update and announced financial results for the quarter ended September 30, 2025. The details are contained in a press release attached as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Common stock trades on Nasdaq under ALLO.
Allogene Therapeutics, Inc. filed a current report to note that it has released a corporate update and its financial results for the quarter ended June 30, 2025. The details are contained in a press release dated August 13, 2025, which is included as Exhibit 99.1 and incorporated by reference.
The company specifies that this information is being furnished under the rules of the Securities Exchange Act and is not deemed filed for liability purposes. The filing is signed by President and Chief Executive Officer David Chang, M.D., Ph.D.
Allogene Therapeutics (Nasdaq: ALLO) filed a Form 8-K reporting the voting results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
- Director elections: Stockholders re-elected Elizabeth Barrett (131,435,760 FOR), Arie Belldegrun M.D. (150,891,245 FOR) and David Chang M.D. Ph.D. (153,721,017 FOR) as Class I directors, each to serve until the 2028 annual meeting. Broker non-votes totaled 33,512,034 shares.
- Executive compensation: The non-binding advisory vote approved the compensation of named executive officers with 139,947,868 FOR versus 14,233,309 AGAINST and 3,184,237 abstentions.
- Auditor ratification: Ernst & Young LLP was confirmed as independent registered public accounting firm for fiscal 2025 with 190,111,256 FOR and only 414,604 AGAINST.
No other items were presented. The filing contains no updates on financial performance, strategic initiatives, or legal matters.